Discovery of pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives as novel CDK2 inhibitors: synthesis, biological and molecular modeling investigations.

ABSTRACT: CDK2 inhibition is an appealing target for cancer treatment that targets tumor cells in a selective manner. A new set of small molecules featuring the privileged pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffolds (4-13) as well as the thioglycoside derivatives (14, 15) were designed, and synthesized as novel CDK2 targeting compounds. The growth of the three examined cell lines was significantly inhibited by most of the prepared compounds. Results revealed that most of the compounds showed superior cytotoxic activities against MCF-7 and HCT-116 with IC₅₀ range (45-97 nM) and (6-99 nM), respectively, and moderate activity against HepG-2 with IC₅₀ range of (48-90 nM) compared to sorafenib (IC₅₀: 144, 17

SUBMITTER: Nassar IF 

PROVIDER: S-EPMC9112407 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature